Sanofi (SNY) Stock Forecast & Price Target

Q: What analysts cover Sanofi?

Sanofi has been rated by research analysts at Argus , BNP Paribas Exane , Citigroup , Morgan Stanley , Sanford C. Bernstein , and Weiss Ratings in the past 90 days.

$42.63 -0.33 (-0.76%)

As of 02:30 PM Eastern

Compare

Sanofi - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 15 Analyst Ratings

Sell
0

Hold
10

Buy
5

Based on 15 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 10 have given a hold rating, 3 have given a buy rating, and 2 have given a strong buy rating for SNY.

Consensus Price Target

$51.00
19.62% Upside

According to the 15 analysts' twelve-month price targets for Sanofi, the average price target is $51.00. The highest price target for SNY is $52.00, while the lowest price target for SNY is $50.00. The average price target represents a forecasted upside of 19.62% from the current price of $42.63.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNY Analyst Ratings Over Time

Type	Current Forecast 6/2/25 to 6/2/26	1 Month Ago 5/3/25 to 5/3/26	3 Months Ago 3/4/25 to 3/4/26	1 Year Ago 6/2/24 to 6/2/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)	3 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)
Hold	10 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$51.00	$51.00	$62.67	$63.33
Forecasted Upside	19.62% Upside	10.68% Upside	35.58% Upside	28.75% Upside
Consensus Rating	Hold	Hold	Hold	Buy

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sanofi Stock vs. The Competition

Type	Sanofi	Medical Companies	Broader Market
Consensus Rating Score	2.47	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	18.72% Upside	1,727.29% Upside	15.25% Upside
News Sentiment Rating	Positive News See Recent SNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/13/2026	Weiss Ratings Not Rated		Upgrade	Sell (D+) ➝ Hold (C-)
5/1/2026	Morgan Stanley 3 of 5 stars		Set Target		$52.00	+12.85%
4/27/2026	Argus 3 of 5 stars		Upgrade	Strong-Buy
4/20/2026	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$50.00	+4.04%
4/13/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
3/19/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
2/12/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/16/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emmanuel Papadakis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
1/16/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Weston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
1/6/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight
Stranded On The Flood Plains of History (Ad) The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar. Read Porter's full briefing and get the ticker names today
12/30/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
12/10/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
12/9/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/8/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Vosser Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
10/27/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
3/21/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Quigley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00	+12.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:31 PM ET.

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 29, 2026. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi recently increased its annual dividend to $2.4225, reflecting a strong commitment to returning value to shareholders.
The current stock price is around $45.95, which is considered attractive given the company's solid fundamentals.
Analysts have a consensus rating of "Hold" with a price target of $51.00, indicating potential for price appreciation.
Sanofi has a low debt-to-equity ratio of 0.17, suggesting a strong balance sheet and lower financial risk.
The company operates in diverse therapeutic areas, including oncology and immunology, which can provide stability and growth opportunities.

Sanofi
Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

Despite the recent dividend increase, the payout ratio is 49.44%, which may limit future dividend growth.
Sanofi's quick ratio of 0.22 indicates potential liquidity issues, as it suggests the company may struggle to meet short-term obligations.
Recent analyst ratings show a mix of "Hold" and "Buy," with some analysts downgrading their ratings, which may indicate uncertainty in the stock's performance.
The stock has experienced fluctuations, with a 12-month high of $55.73 and a low of $43.32, reflecting volatility that could deter risk-averse investors.
Market conditions and competition in the pharmaceutical sector can impact Sanofi's growth prospects and profitability.

SNY Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $51.00, with a high forecast of $52.00 and a low forecast of $50.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 10 hold ratings, 3 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNY, but not buy additional shares or sell existing shares.

According to analysts, Sanofi's stock has a predicted upside of 19.62% based on their 12-month stock forecasts.

Over the previous 90 days, Sanofi's stock had 4 upgrades and 4 downgrades by analysts.

Sanofi has been rated by research analysts at Argus, BNP Paribas Exane, Citigroup, Morgan Stanley, Sanford C. Bernstein, and Weiss Ratings in the past 90 days.

Analysts like Sanofi more than other "medical" companies. The consensus rating score for Sanofi is 2.47 while the average consensus rating score for "medical" companies is 2.30. Learn more on how SNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Sanofi Recommendations

This page (NASDAQ:SNY) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Stock Forecast & Price Target